Clinical Trial

Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated due to a strategic prioritization and realignment of the research and development portfolio by the study team.
Summary
Panic attacks affect 13.2% of adults globally, with acute treatments (e.g., benzodiazepines) carrying dependency risks. Dexmedetomidine, an α₂-adrenergic agonist, achieves peak plasma levels in 5-15 min via nasal delivery and may offer rapid, non-invasive relief for acute panic attacks. Despite preclinical evidence of anxiolytic effects, no randomized trials have evaluated its efficacy for panic attacks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-01.
Status change: Not Yet Recruiting → Withdrawn 2026-04-15
Trial Details
NCT Number NCT07162649
Lead Sponsor Tongji University
Collaborators: Shanghai 10th People's Hospital, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Conditions Dexmedetomidine
Start Date 2025-09-01
Primary Completion 2027-08-30 (estimated)
Study Completion 2028-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-20